News

Financial terms of the transaction were not disclosed by both the companies, however, sources familiar with the development have been cited by Reuters as saying that the deal

BAY 81-8973 is a full-length recombinant factor VIII which has demonstrated clinical evidence of efficacy when used for prophylaxis twice or three times per week, with standard dosages.

Designed to slow down tumor growth, the FPA144 prevents the binding of fibroblast growth factors to FGF receptor 2b (FGFR2b) and is being developed initially as a monotherapy

Under the deal, Pfizer will review medicines that are currently under development to find substances with a probable or high risk of abuse in sport. The company will

Reassuring Member States over safety of flu vaccine, the review conducted by the committee found that the vaccine was safe for administration in vaccination campaigns. The review follows

A novel screening approach has been developed by Monash University researchers, led by Professor David Jans in the Department of Biochemistry, to identify new classes of antiviral drugs.

In an emailed statement, a GSK spokesman was quoted by Reuters as saying: "This is a significant programme and will result in the loss of several hundred employees

This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. With this approval, BLINCYTO becomes

The multi-year grants that worth about $3.5m will be used for the projects that focus on hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in high-risk